23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

23andMe Holding Co.

Lemonaid Health (part of 23andMe)

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was named as one of the San Francisco Chronicle's Top Workplaces and one of Comparably's Best Places to Work in 2022. CEO, Anne Wojcicki was also named one of Glassdoor’s top CEOs in 2019 and one of Comparably’s "Best CEOs for Women" in 2021 and 2022. More information is available at www.23andMe.com.

Doctor On Demand

GlaxoSmithKline

Casdin Capital

Fidelity

Fidelity Management and Research Company

Foresite Capital

Altimeter Capital

Anne Wojcicki

Richard Branson

Sean Tiner

Future Planet Capital

Raj Luhar

SharesPost Investment Management

NewView Capital

Pegasus Tech Ventures

Sequoia Capital

ACE & Company

Rancilio Cube

23andMe

This #BlackHistoryMonth, we’re sharing quotes from Black leaders in STEM who continue to inspire us every day. Mae Jemison became the first African-American woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour in 1992.

We’re looking for a Sr. Scientist II to join our Research Team! In this role, you will have the opportunity to provide scientific input and strategic direction for research initiatives involving the lung cancer cohort. https://lnkd.in/guC-u3bT

Earlier this year, researchers with the National Institutes of Health, in collaboration with 23andMe and about a dozen other groups, published the largest to-date genetic study of Parkinson’s disease. This is the first large-scale genetics study of Parkinson’s disease to include data from individuals from multiple ancestral populations. 

https://23and.me/3SmIqHS

We are excited to announce the U.S. FDA has cleared the investigational new drug application for 23ME-01473 (‘1473), a natural killer (NK) cell activator intended to treat cancer.

“This program further validates the 23andMe database as a proven resource for identifying novel therapeutic targets,” said Jennifer Low, Head of Therapeutics Development, 23andMe. “The team is excited to initiate our next immuno-oncology program, ‘1473, which is particularly interesting given its two mechanisms of action, which may synergise to enhance NK and T cell immunity against certain tumors.” 

Read more here: https://lnkd.in/gKQMP6Ka

Has there ever been a time – maybe during a stressful moment, or even just out of the blue – when you started to feel dizzy, like your vision was narrowing, and like you were disconnected from your body? 

About 1 in 3 people will experience a panic attack in their lifetime. Panic attacks happen when fear and anxiety overwhelm a person and lead to physical symptoms such as a racing heart, stomach aches, or shortness of breath. 

Our 23andMe+ Premium Panic Attacks report (Powered by 23andMe Research) helps individuals better understand their genetic likelihood of developing panic attacks throughout their lifetime. https://23and.me/426saOl

We're excited to share that the FDA  included our BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report clearance and PCCP in their 2023 Annual Report for device innovation. 

Check out the report here: https://lnkd.in/evgJZnXh

January is Thyroid Awareness Month. In 2022, we released a 23andMe+ Premium report on Hashimoto’s disease, powered by 23andMe research. 

Hashimoto’s disease is an autoimmune condition in which the immune system causes the thyroid gland to become inflamed and damaged, and over time produce less thyroid hormone. This condition can cause many different symptoms like fatigue or depression, and if left untreated, can be associated with other health conditions like heart problems. 

Members can learn about their genetic likelihood of developing it and actions they can take to promote thyroid and immune health. https://23and.me/3u87E3n

Our very own Dr. Noura Abul-Husn is speaking at the Precision Medicine World Conference this week in Silicon Valley on January 25th! If you’re planning to attend make sure you stop by for her showcase.

At 23andMe, we believe the ability to identify, recruit, and characterize research participants based on genetics unknown to them is a critical capability for our therapeutics and research teams to inform drug development and genetics research.

https://23and.me/48zaTQv

When Emily decided to do a 23andMe, she expected to learn more about her health, genealogy, and all of the “fun stuff DNA can tell you,” but her results led to something unexpected, and expanded what she understood about herself and her family. 

https://23and.me/3HnVW7O

	Mar '19	Mar '20	Mar '21	Mar '22	Mar '23	Mar '24
account payables	45.68M -	13.09M 71.35%	12.27M 6.22%	37.93M 209.10%	12.92M 65.93%	11.57M 10.47%
accumulated other comprehensive income loss				179K -	-620K 446.37%
cash and cash equivalents	452.75M -	209.34M 53.76%	282.49M 34.94%	553.18M 95.82%	386.85M 30.07%	217.89M 43.68%
cash and short term investments	452.75M -	209.34M 53.76%	282.49M 34.94%	553.18M 95.82%	386.85M 30.07%	217.89M 43.68%
common stock				45K -	46K 2.22%	49K 6.52%
deferred revenue		84.09M -	71.25M 15.26%	62.94M 11.67%	62.52M 0.66%	64.83M 3.69%
deferred revenue non current		3.37M -				10M -
deferrred tax liabilities non current						-1 -
goodwill				351.74M -	351.74M 0%
goodwill and intangible assets	510K -	5.42M 962.16%	6.89M 27.17%	435.28M 6,218.54%	412.93M 5.14%	53.77M 86.98%
intangible assets	510K -	5.42M 962.16%	6.89M 27.17%	83.54M 1,112.66%	61.18M 26.76%	53.77M 12.11%
inventory	13.68M -	14.12M 3.22%	6.24M 55.82%	10.79M 72.93%	10.25M 5.02%	12.46M 21.65%
long term debt			87.58M -	78.52M 10.34%	77.76M 0.97%	67.84M 12.75%
long term investments		7.83M -				6.97M -
net debt	-452.75M -	-119.02M 73.71%	-188.77M 58.60%	-466.87M 147.33%	-301.55M 35.41%	-141.37M 53.12%
net receivables	10.60M -	6.39M 39.69%	2.48M 61.19%	3.38M 36.24%	1.90M 43.88%	3.32M 75.22%
other assets	8.68M -					1 -
other current assets	36.95M -	16.02M 56.64%	22.37M 39.60%	34.44M 53.97%	19.22M 44.18%	16.84M 12.40%
other current liabilities	141.19M -	34.66M 75.45%	31.95M 7.81%	44.59M 39.54%	66.43M 48.99%	42.26M 36.38%
other liabilities	115.18M -					1 -
other non current assets	-174.03M -	7.87M 104.52%	7.63M 3.11%	9.57M 25.42%	9.99M 4.47%	-13.86M 238.63%
other non current liabilities		127.61M -	838.52M 557.10%	4.65M 99.45%	1.48M 68.15%	1.47M 0.61%
othertotal stockholders equity	101.47M -	172.74M 70.23%	381.62M 120.93%	2.11B 452.95%	2.22B 5.25%	2.36B 6.33%
preferred stock	755.08M -	755.08M 0%
property plant equipment net	173.52M -	137.64M 20.68%	124.01M 9.90%	105.43M 14.98%	94.69M 10.19%	77.25M 18.42%
retained earnings	-542.76M -	-793.62M 46.22%	-977.24M 23.14%	-1.19B 22.26%	-1.51B 26.09%	-2.17B 44.26%
short term debt		7.61M -	6.14M 19.35%	7.78M 26.78%	7.54M 3.12%	8.67M 14.97%
short term investments
tax assets						20.52M -
tax payables			335K -	2.04M 507.76%	1.36M 33.40%	1.11M 18.29%
total assets	696.68M -	404.63M 41.92%	452.10M 11.73%	1.15B 154.83%	942.60M 18.18%	395.17M 58.08%
total current assets	513.98M -	245.88M 52.16%	313.57M 27.53%	601.79M 91.91%	424.99M 29.38%	250.52M 41.05%
total current liabilities	186.86M -	139.45M 25.37%	121.62M 12.79%	153.24M 26.00%	149.42M 2.50%	127.33M 14.78%
total debt		90.32M -	93.72M 3.76%	86.31M 7.91%	85.30M 1.16%	76.52M 10.30%
total investments		7.83M -				6.97M -
total liabilities	382.88M -	270.43M 29.37%	1.05B 287.43%	236.41M 77.44%	228.66M 3.28%	206.65M 9.63%
total liabilities and stockholders equity	696.68M -	404.63M 41.92%	452.10M 11.73%	1.15B 154.83%	942.60M 18.18%	395.17M 58.08%
total non current assets	174.03M -	158.75M 8.78%	138.52M 12.74%	550.28M 297.25%	517.61M 5.94%	144.65M 72.05%
total non current liabilities		130.98M -	926.10M 607.04%	83.17M 91.02%	79.24M 4.72%	79.32M 0.09%
total stockholders equity	313.80M -	134.20M 57.23%	-595.62M 543.83%	915.66M 253.73%	713.94M 22.03%	188.52M 73.59%

COM:23ANDME

23andMe Holding Co.

Last Close

3.23

22/11 21:00

Market Cap

225.52M

Beta: -

Volume Today

514.98K

Avg: -

Preview